Cylene Pharmaceuticals Overview
- Year Founded
-
1997
- Status
-
Out of Business
- Employees
-
3
- Latest Deal Type
-
Out of Business
Cylene Pharmaceuticals General Information
Description
Developer of small molecule drugs designed to target against newly validated cancer. The company's small molecule drugs delivers first-in-class targeted agents that act through the ideal non-genotoxic pathway for activating p53 to kill cancer cells, enabling physicians to offer improved treatment outcomes against many cancer indications.
Contact Information
Website
www.cylenepharma.comCorporate Office
- 5820 Nancy Ridge Drive
- Suite 200
- San Diego, CA 92121
- United States
Corporate Office
- 5820 Nancy Ridge Drive
- Suite 200
- San Diego, CA 92121
- United States
Cylene Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Out of Business | 01-Apr-2013 | Completed | Out of Business | |||
| 8. Later Stage VC | 18-Jan-2013 | Completed | Profitable | |||
| 7. Later Stage VC (Series C) | 27-Sep-2010 | Completed | Profitable | |||
| 6. Grant | 31-Dec-2009 | Completed | Profitable | |||
| 5. Later Stage VC (Series C) | 23-Jan-2007 | Completed | Profitable | |||
| 4. Later Stage VC (Series B) | 25-May-2005 | Completed | Profitable | |||
| 3. Later Stage VC (Series A) | 03-May-2004 | Completed | Profitable | |||
| 2. Later Stage VC | 24-Mar-2003 | $1.22M | $4.77M | Completed | Profitable | |
| 1. Early Stage VC (Series A) | 17-Oct-2001 | $3.55M | $3.55M | Completed | Profitable |
Cylene Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 6,513,212 | $0.001000 | $0.08 | $1 | $1 | 1x | $1 | 5.97% |
Cylene Pharmaceuticals Patents
Cylene Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2022179783-A | Crystal forms of quinolone analogues and their salts | Pending | 28-Aug-2020 | ||
| JP-2020189888-A | Quinolone analog and form of salt thereof | Inactive | 28-Aug-2020 | ||
| JP-2022020003-A | Combination therapy of tetracyclic quinolone analogs to treat cancer | Inactive | 20-Nov-2015 | ||
| WO-2012170827-A2 | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors | Inactive | 08-Jun-2011 | ||
| WO-2012054493-A1 | Deuterated serine-threonine protein kinase modulators | Inactive | 22-Oct-2010 | A61K31/44 |
Cylene Pharmaceuticals Signals
Cylene Pharmaceuticals FAQs
-
When was Cylene Pharmaceuticals founded?
Cylene Pharmaceuticals was founded in 1997.
-
Where is Cylene Pharmaceuticals headquartered?
Cylene Pharmaceuticals is headquartered in San Diego, CA.
-
What is the size of Cylene Pharmaceuticals?
Cylene Pharmaceuticals has 3 total employees.
-
What industry is Cylene Pharmaceuticals in?
Cylene Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Cylene Pharmaceuticals a private or public company?
Cylene Pharmaceuticals is a Private company.
-
What is Cylene Pharmaceuticals’s current revenue?
The current revenue for Cylene Pharmaceuticals is .
-
How much funding has Cylene Pharmaceuticals raised over time?
Cylene Pharmaceuticals has raised $106M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process